Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
about
Tackling dengue fever: Current status and challengesDengue Fever: Causes, Complications, and Vaccine StrategiesEndothelial cells in dengue hemorrhagic feverLatest developments and future directions in dengue vaccinesDengue research opportunities in the AmericasAntibody responses to Zika virus infections in flavivirus-endemic environmentsInduction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States.Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cellsDengue vaccines: state of the art.Utility, limitations, and future of non-human primates for dengue research and vaccine developmentDengue vaccines: recent developments, ongoing challenges and current candidates.Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, MexicoDengue vaccines: strongly sought but not a reality just yetThe protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2The contribution of non-human primate models to the development of human vaccinesRecombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated VaccineSafety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.Dengue fever and dengue haemorrhagic fever in adolescents and adults.Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysisSculpting humoral immunity through dengue vaccination to enhance protective immunityTesting of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacyA molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.Recent progress in dengue vaccine development.Antibody recognition of the dengue virus proteome and implications for development of vaccines.Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates.Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine.Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
P2860
Q24288867-ED626D66-3585-45A7-89C8-8D7F035F70A2Q26700082-916A2C92-1FA2-4B52-A80D-2B572D07AA38Q26825663-A50937D1-8333-440C-B232-327BF137D276Q27023422-6571D430-1DA8-4D23-8BB4-929550802478Q28656204-407E509F-649D-40AB-83FB-4ABE2ED5CB71Q28827957-E4D0AB27-7639-43F7-BE56-C796CB730AE5Q33699057-CDD8D56A-FD5C-4E1A-BA51-CAFDB0078034Q33723518-1ED5F03A-7D65-4962-B75C-543527CAF9CEQ33773563-B50C2228-E60E-4502-90CE-A03DF454813FQ33955239-6538BE81-DE69-4BDE-8399-1CFB3AC79F21Q34109652-AEBBF1C7-C192-47BC-BF8D-BD63632F4A63Q34238916-0BFDB3CA-A66D-4664-AC08-DFE55D8021B8Q34367194-EA47D014-A212-408A-B3AC-CABCB9703270Q34496118-091D340F-65C0-48E8-8FD2-09B51CBE1CC0Q35008771-6EE27F9B-592B-48CA-A064-863F6B84CB91Q35236379-2E58DC93-0F84-4DC9-938C-679C9014B519Q35272502-D53DB38F-A292-4CEA-BA91-80153136CAADQ35624552-027FEDC5-F866-4B8E-86FC-539728210F86Q35737990-A6097C68-317F-4281-B389-9A5E5BF96086Q35976650-1C4CF193-782B-4FC5-8C74-04FB4B47E2EFQ36026210-B1FA296C-E557-4067-AD60-750B6C3C52A8Q36053269-6812B692-9804-47AC-B829-EA235D5D4FEEQ36082908-AB59B059-368B-4A88-993D-D853F5D099FFQ36382589-3F98737B-0280-4CA6-A452-CBC688163B09Q36450864-C7E224AF-9297-4930-A80B-20CA9979E976Q37812291-DA0EEBD4-5A5D-45A2-96FD-9C933BBD9B28Q38303232-88DBEE33-F2B9-47F2-BC2C-0F6F61552808Q39002738-BBE16C48-C146-42B9-903D-805586276916Q40081626-753302AB-EC64-4B23-A69B-C55F78D4F455Q40130106-7EB8C40F-CDAE-4195-930B-23782B0AC791Q40338292-89CA3131-289C-4F67-99E4-A32F62B8521DQ40423085-9A4B7A45-CC7C-41AE-85A0-7DFA2EC34789Q54260853-B080A2B6-FA59-4A96-933B-469C1A59DC24
P2860
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Protection against dengue viru ...... me boost vaccination strategy.
@en
type
label
Protection against dengue viru ...... me boost vaccination strategy.
@en
prefLabel
Protection against dengue viru ...... me boost vaccination strategy.
@en
P2093
P1433
P1476
Protection against dengue viru ...... me boost vaccination strategy.
@en
P2093
Julia Lynch
Monika Simmons
Robert Putnak
Timothy Burgess
P304
P356
10.1016/J.VIROL.2009.10.023
P407
P577
2009-11-13T00:00:00Z